Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Morphotek
ClinicalTrials.gov Identifier:
NCT00318370
First received: April 24, 2006
Last updated: November 5, 2013
Last verified: November 2013

April 24, 2006
November 5, 2013
May 2006
February 2010   (final data collection date for primary outcome measure)
  • Serologic Response (Change in CA125 Level) [ Time Frame: Baseline to response (up to 30 weeks) ] [ Designated as safety issue: No ]
    Defined using modified Gynecologic Cancer Intergroup (GCIG) criteria: Number of participants who achieved a 50% response = >50% decrease from baseline CA-125 (higher of 2 pretreatment CA-125 assessments and the level must be at least 52.5 kU/L).
  • Serologic Response (Change in Cancer Antigen [CA-125] Level) [ Time Frame: Baseline to response (up to 27 weeks) ] [ Designated as safety issue: No ]
    Defined using modified Gynecologic Cancer Intergroup (GCIG) criteria: Number of participants who had a 50% response = >50% decrease from baseline CA-125 (higher of 2 pretreatment CA-125 assessments and the level must be at least 52.5 kU/L).
  • Change in CA125 level
  • Overall Response Rate by RECIST Criteria
  • Progression free survival
  • Prolongation of response
  • Disease-free survival
  • Overall survival
Complete list of historical versions of study NCT00318370 on ClinicalTrials.gov Archive Site
  • Time to Serologic Response (Change in CA-125 Level) [ Time Frame: Baseline to response (up to 27 weeks) ] [ Designated as safety issue: No ]
    Time to Serologic Response is defined as the time (weeks) from the date of first farletuzumab infusion to first documentation of 50% decrease from baseline CA-125 (higher of 2 pretreatment CA-125 assessments and at least twice the upper limit of normal) and then confirmed after 21 days.
  • Duration of Serologic Response (CA-125) [ Time Frame: Baseline to response (up to 44 months) ] [ Designated as safety issue: No ]
    Calculated as the time from the first documentation of 50% or greater reduction in CA-125 to the first documentation of serologic progression or death due to any cause. Serologic progression was defined as the first date of the CA-125 level being >2 X ULN on two occasions.
  • Overall Response Rate [ Time Frame: Baseline to response (up to 44 months) ] [ Designated as safety issue: No ]
    The Overall Response Rate (ORR) will be determined by applying standard RECIST criteria to objective measures of disease, such as CT or MRI scans. Participants will be assigned to one of the categories of change in disease status, namely, "complete response" (CR), "partial response" (PR), "stable disease" (SD), or "progressive disease" (PD). ORR is defined as the percentage of participants with objective evidence of CR or PR.
  • Progression-free Survival (PFS) [ Time Frame: Baseline to response (up to 44 months) ] [ Designated as safety issue: No ]
    PFS is defined for participants treated in Chemo Plus Far as the time (in months) from date of first dose in Chemo Plus Far until date of the first observation of progression based on first date of the CA-125 >2 X ULN on two occasions, or date of death, whatever the cause. If progression or death is not observed for a participant, the PFS time is censored at the later date of last tumor assessment or CA125 assessment without evidence of progression prior to the date of initiation of further anti-tumor treatment.
  • Percentage of Participants Who Had a Prolongation of Remission [ Time Frame: Baseline to response (up to 44 months) ] [ Designated as safety issue: No ]
    Percentage of participants whose second remission was longer than their first remission. The length of remission will be determined for participants who attain CR or PR (or SD and investigator's assessment of clinical benefit). Prolongation of remission will be defined as a length of remission occurring on this study that is ≥ 1 day longer than the length of remission to the original therapy. The length of remission on this study (second remission) will be defined as the amount of time from the date of first CR or PR to the end of this remission.
  • Safety
  • Pharmacokinetics
Not Provided
Not Provided
 
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse

The purpose of this study is to determine if an investigational drug called MORAb-003 is useful by itself or when used with other approved cancer drugs in treating women with ovarian cancer. MORAb-003 is a monoclonal antibody directed against an antigen on most ovarian cancers.

MORAb-003 is a monoclonal antibody that has the potential to be an effective agent against epithelial ovarian cancer (including primary fallopian tube and peritoneal adenocarcinoma) either alone or in combination with other drugs. MORAb-003 works by a different mechanism from other cancer therapeutics and has been shown to be well tolerated. This study allows the opportunity to determine if MORAb-003 can work either as a single agent

  1. to treat a CA125-only relapse, or
  2. in combination with standard platinum and taxane chemotherapy to treat a symptomatic relapse, and
  3. to prolong a second response to chemotherapy.
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Neoplasms
  • Drug: Farletuzumab
    Weekly Farletuzumab infusions Dose dependent on dosing group
    Other Names:
    • MORAb-003
    • Far Only
  • Drug: Chemo Plus Far
    Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
  • Experimental: Far Only
    Farletuzumab only (Far Only): farletuzumab, 100 milligrams (mg)/square meter (m2).
    Intervention: Drug: Farletuzumab
  • Experimental: Chemo Plus Far
    Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
    Intervention: Drug: Chemo Plus Far
Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol. 2013 Jun;129(3):452-8. doi: 10.1016/j.ygyno.2013.03.002. Epub 2013 Mar 6.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
58
June 2010
February 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female subjects at least 18 years of age, with a histologically confirmed diagnosis of non-mucinous epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) in first relapse after a first remission of 6 to 18 months duration.
  • Subjects must have undergone surgery. Subjects must have received primary chemotherapy, including at least one platinum agent.
  • Subject is eligible for retreatment with the same chemotherapy regimen that was used to induce remission (Exception: may reduce the dose of or discontinue taxane if contraindicated due to neurotoxicity.)
  • CA125 must have been elevated prior to original chemotherapy.
  • CA125 must be elevated at the time of relapse.
  • Life expectancy greater than or equal to 6 months, as estimated by the investigator.
  • Eastern Cooperative Oncology Group performance status of 0, 1 or 2
  • Subjects must consent to use a medically acceptable method of contraception throughout the study period and for 28 days after final MORAb-003 administration, unless surgically sterile.
  • Any significant concomitant medical conditions must be well controlled and stable in the opinion of the investigator for at least 30 days prior to Study Day 1.
  • Laboratory and clinical results within the 2 weeks prior to Study Day 1 as follows:

    • Absolute neutrophil count (ANC) ≥ 1.2 x 10e9/L
    • Platelet count ≥ 100 x 10e9/L
    • Hemoglobin ≥ 8 g/dL
  • Subject must be willing and able to provide written informed consent. Translations of informed consent information may be provided, subject to the local institutional review board's (IRB's) policy.

Exclusion Criteria:

  • Known central nervous system (CNS) tumor involvement.
  • Evidence of other active malignancy requiring treatment.
  • Clinically significant heart disease (e.g., congestive heart failure of New York Heart Association Class III or IV, angina not well controlled by medication, or myocardial infarction within 6 months).
  • Electrocardiogram (ECG) demonstrating clinically significant arrhythmias (Exception: Subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia [SVT], are eligible).
  • Active serious systemic disease, including active bacterial or fungal infection.
  • Active hepatitis or HIV infection.
  • Treatment within three months with immunomodulatory therapy (e.g. interferons, immunoglobulin therapy, interleukin 1 receptor antagonist [IL-1RA] or systemic corticosteroids). Short term systemic corticosteroids or topical or intra-articular steroids are acceptable, subject to the judgment of the investigator.
  • Treatment with a monoclonal antibody therapy AND have evidence of an immune or allergic reaction or documented HAHA.
  • Maintenance of first remission by taxane or other chemotherapeutic agent(s).
  • Initiation or planned initiation of cancer therapy not given to induce primary remission. Substitutions of agents materially similar to those used in the original regimen are permissible.
  • Breast-feeding, pregnant, or likely to become pregnant during the study.
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Germany
 
NCT00318370
MORAb-003-002
No
Morphotek
Morphotek
Not Provided
Study Director: Susan C. Weil, M.D. Morphotek, Inc.
Morphotek
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP